RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: similarities and main differences for prognosis and therapies

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596 · see citing works

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Fitzmaurice, C., Allen, C., Barber, R. M., Barregård, L., Bhutta, Z. A., Brenner, H., Dicker, D., Chimed‐Ochir, O., Dandona, R., Dandona, L., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,229 · see citing works

WHO Classification of Tumours of the Digestive System

Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 4,814 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial

Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,916 · see citing works

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · see citing works

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517 · see citing works

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,446 · see citing works

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Planchard, D., Smit, E. F., Groen, H. J. M., Mazières, J., Besse, B., Helland, Å., Giannone, V., D'amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360 · see citing works

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works

Progress and prospects of early detection in lung cancer

Knight, S., Crosbie, P. A. J., Balata, H., Chudziak, J., Hussell, T., & Dive, C. (2017) · Open Biology · doi:10.1098/rsob.170070 · Cited by 945 · see citing works

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888 · see citing works

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850 · see citing works

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Fuchs, C. S., Marshall, J. L., Mitchell, E. P., Wierzbicki, R. F., Ganju, V., Jeffery, M., Schulz, J. J., Richards, D., Soufi‐Mahjoubi, R., Wang, B. X., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 849 · see citing works

Epidemiology of Lung Cancer

Alberg, A. J., Brock, M. V., Ford, J. G., Samet, J. M., & Spivack, S. D. (2013) · CHEST Journal · doi:10.1378/chest.12-2345 · Cited by 746 · see citing works

Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · see citing works

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655 · see citing works

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645 · see citing works

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Gainor, J. F., Varghese, A. M., Ou, S. I., Kabraji, S. K., Awad, M. M., Katayama, R., Pawlak, A. C., Mino-Kenudson, M. A., Yeap, B. Y., Riely, G. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0318 · Cited by 609 · see citing works

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598 · see citing works

Carcinoma of the Colon and Rectum

Welch, C. E., & Burke, J. F. (1962) · New England Journal of Medicine · doi:10.1056/nejm196202012660501 · Cited by 566 · see citing works

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552 · see citing works

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · see citing works

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Cutsem, E. V., Rivera, F., Berry, S. R., Kretzschmar, A., Michael, M., Bartolomeo, M. D., Mazier, M., Canon, J.-L., Georgoulias, V., Peeters, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp233 · Cited by 531 · see citing works

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507 · see citing works

Panitumumab versus Cetuximab in Patients with Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study

Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473 · see citing works

A combinatorial strategy for treating KRAS-mutant lung cancer

Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403 · see citing works

Tumor microenvironment and cancer therapy resistance

Sun, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 384 · see citing works

Association of <i>KRAS</i> G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353 · see citing works

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350 · see citing works

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349 · see citing works

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i> -Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · see citing works

Clinical Acquired Resistance to RAF Inhibitor Combinations in <i>BRAF</i> -Mutant Colorectal Cancer through MAPK Pathway Alterations

Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322 · see citing works

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294 · see citing works

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Lee, R. J., Nolop, K. B., & Saltz, L. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3534 · Cited by 283 · see citing works

Diagnosis and Molecular Classification of Lung Cancer

Rodriguez‐Canales, J., Parra-Cuentas, E. R., & Wistuba, I. I. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_2 · Cited by 277 · see citing works

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Kohno, T., Nakaoku, T., Tsuta, K., Tsuchihara, K., Matsumoto, S., Yoh, K., & Goto, K. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2014.11.11 · Cited by 263 · see citing works

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242 · see citing works

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233 · see citing works

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 212 · see citing works

Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 211 · see citing works

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A. J., Townsend, A. R., Wrin, J., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 210 · see citing works

NRAS Mutations Are Rare in Colorectal Cancer

Irahara, N., Baba, Y., Nosho, K., Shima, K., Yan, L., Dias-Santagata, D. C., Iafrate, A. J., Fuchs, C. S., Haigis, K. M., & Ogino, S. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181c93fd1 · Cited by 196 · see citing works

Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147

Gonsalves, W. I., Mahoney, M. R., Sargent, D. J., Nelson, G. D., Alberts, S. R., Sinicrope, F. A., Goldberg, R. M., Limburg, P. J., Thibodeau, S. N., Grothey, A. F., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju106 · Cited by 169 · see citing works

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF –Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Yoon, H. H., Tougeron, D., Shi, Q., Alberts, S. R., Mahoney, M. R., Nelson, G. D., Nair, S., Thibodeau, S. N., Goldberg, R. M., Sargent, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3140 · Cited by 155 · see citing works

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

Murray, S. J., Dahabreh, I. J., Linardou, H., Manoloukos, M., Bafaloukos, D. I., & Kosmidis, P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818071f3 · Cited by 153 · see citing works

Molecular Diagnostics in Clinical Oncology

Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 144 · see citing works

Characteristics of Lung Cancers Harboring NRAS Mutations

Ohashi, K., Sequist, L. V. D., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Morán, T., Camidge, D. R., Vnencak‐Jones, C. L., Berry, L. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 142 · see citing works

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Bennouna, J., Láng, I., Valladares‐Ayerbes, M., Boér, K., Adenis, A., Escudero, P., Kim, T. Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 141 · see citing works

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

Yu, H. A., Sima, C. S., Shen, R., Kass, S. L., Gainor, J. F., Shaw, A. T., Hames, M. L., Iams, W. T., Aston, J. L., Lovly, C. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000432 · Cited by 137 · see citing works

Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK

Tolcher, A. W., Khan, K. H., Ong, M., Banerji, U., Papadimitrakopoulou, V. A., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 137 · see citing works

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 131 · see citing works

Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer

Yaeger, R. D., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Seventer, E. E. V., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 127 · see citing works

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

Sen, B., Peng, S., Tang, X., Erickson, H. S., Galindo, H., Mazumdar, T., Stewart, D. J., Wistuba, I. I., & Johnson, F. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003513 · Cited by 111 · see citing works

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

Stintzing, S., von Weikersthal, L. F., Decker, T. W., Vehling‐Kaiser, U., Jäger, E., Heintges, T., Stoll, C. G., Giessen, C. A., Modest, D. P., Neumann, J. H. L., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr571 · Cited by 111 · see citing works

DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer

Mamlouk, S., Childs, L. H., Aust, D. E., Heim, D., Melching, F., de Oliveira, C. M. M., Wolf, T. A., Durek, P., Schumacher, D., Bläker, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14093 · Cited by 111 · see citing works

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer

Tougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 110 · see citing works

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V. R., Yan, J. J., Pham, L. Q., Wang, M. M., Bollag, G. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 104 · see citing works

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

Felip, E., Barlési, F., Besse, B., Chu, Q. S.-C., Gandhi, L., Kim, S., Carcereny, E., Sequist, L. V. D., Brunsvig, P. F., CHOUAID, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.131 · Cited by 96 · see citing works

Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer

Datta, J., Smith, J. J., Chatila, W. K., McAuliffe, J. C., Kandoth, C., Vakiani, E., Frankel, T. L., Ganesh, K., Wasserman, I., Lipsyc-Sharf, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2390 · Cited by 93 · see citing works

Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells

Martinelli, E., Troiani, T., Morgillo, F., Rodolico, G., Vitagliano, D., Morelli, M. P., Tuccillo, C., Vecchione, L., Capasso, A., Orditura, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0923 · Cited by 90 · see citing works

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

LoRusso, P. M., Krishnamurthi, S., Rinehart, J. J., Nabell, L., Croghan, G. A., Varterasian, M. L., Sadis, S., Menon, S. S., Leopold, J., & Meyer, M. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3011 · Cited by 89 · see citing works

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0234-3 · Cited by 81 · see citing works

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer

Köhne, C., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Gamelin, E. C., DeCosta, L., & Karthaus, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1061-6 · Cited by 80 · see citing works

Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern

Al-Shamsi, H. O., Jones, J. C., Fahmawi, Y., Dahbour, I., Tabash, A., Abdel‐Wahab, R., Abousamra, A., Shaw, K. R. M., Xiao, L., Hassan, M. M., et al. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.02 · Cited by 78 · see citing works

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

Taı̈eb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 77 · see citing works

Characterization of rare transformingKRASmutations in sporadic colorectal cancer

Tong, J. H., Lung, R. W. M., Sin, F. M., Law, P. P. Y., Kang, W., Chan, A. W. H., Ma, B. B. Y., Mak, T. W. C., Ng, S. S., & To, K. F. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28550 · Cited by 76 · see citing works

MEK inhibitors under development for treatment of non-small-cell lung cancer

Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 73 · see citing works

Tumor Heterogeneity Revealed byKRAS,BRAF, andPIK3CAPyrosequencing:KRASandPIK3CAIntratumor Mutation Profile Differences and Their Therapeutic Implications

Kosmidou, V., Oikonomou, E., Vlassi, M., Avlonitis, S., Katseli, A., Tsipras, I., Mourtzoukou, D., Kontogeorgos, G., Zografos, G., & Pintzas, A. (2013) · Human Mutation · doi:10.1002/humu.22496 · Cited by 72 · see citing works

Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution

Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 69 · see citing works

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

Bracht, J. W. P., Karachaliou, N., Bivona, T., Lanman, R. B., Faull, I., Nagy, R. J., Drozdowskyj, A., Berenguer, J., Fernandez-Bruno, M., Molina-Vila, M. A., et al. (2019) · Cancers · doi:10.3390/cancers11091381 · Cited by 67 · see citing works

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

Bendell, J. C., Atreya, C. E., André, T., Tabernero, J. M., Gordon, M. S., Bernards, R., Cutsem, E. V., Tejpar, S., Sidhu, R., Go, W. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3515 · Cited by 63 · see citing works

Agents to treat BRAF-mutant lung cancer

Alvarez, J. G. B., & Otterson, G. A. (2019) · Drugs in Context · doi:10.7573/dic.212566 · Cited by 63 · see citing works

Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery

Mao, C., Xiong, M., Liu, Y., Shen, S., Du, X., Yang, X., Dou, S., Zhang, P., & Wang, J. (2014) · Molecular Therapy · doi:10.1038/mt.2014.18 · Cited by 57 · see citing works

Mutant HRAS as novel target for MEK and mTOR inhibitors

Kiessling, M., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G. (2015) · OncoTarget · doi:10.18632/oncotarget.5619 · Cited by 57 · see citing works

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy

Bradbury, P. A., Morris, D. G., Nicholas, G. A., Tu, D., Tehfe, M., Goffin, J. R., Shepherd, F. A., Gregg, R. W., Rothenstein, J. M., Lee, C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.005 · Cited by 57 · see citing works

Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer

Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55 · see citing works

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Goldman, J. W., Shi, P., Reck, M., Paz-Ares, L. G., Koustenis, A. G., & Hurt, K. C. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.08.003 · Cited by 52 · see citing works

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Oliner, K. S., Douillard, J., Siena, S., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3511 · Cited by 52 · see citing works

KRAS: Reasons for optimism in lung cancer

Lindsay, C. R., Jamal‐Hanjani, M., Forster, M. D., & Blackhall, F. H. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 52 · see citing works

Mutation spectra of RAS gene family in colorectal cancer

Chang, Y.-Y., Lin, P.-C., Lin, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Liang, W.-Y., & Chang, S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.02.013 · Cited by 51 · see citing works

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial

Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S. M., Bettini, A., Longo, F., Moscetti, L. I., Ganzinelli, M., Lauricella, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv318 · Cited by 46 · see citing works

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Zheng, D., Chen, H., Wang, R., Zhang, Y., Pan, Y., Cheng, X., Cheng, C., Zheng, S., Li, H., Gong, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96834 · Cited by 44 · see citing works

Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.

van Geel, R. M. J. M., Élez, E., Bendell, J. C., Faris, J. E., Lolkema, M. P., Eskens, F. A. L. M., Spreafico, A., Kavan, P., Delord, J., Schüler, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3514 · Cited by 44 · see citing works

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer

Cui, G., Liu, D., Li, W., Fu, X., Liang, Y., Li, Y., Shi, W., Chen, X., & Zhao, S. Q. (2017) · Medicine · doi:10.1097/md.0000000000006552 · Cited by 43 · see citing works

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation

Fiala, O., Pešek, M., Fínek, J., Minárik, M., Benešová, L., Bortlíček, Z., & Topolčan, O. (2015) · Tumor Biology · doi:10.1007/s13277-015-3249-x · Cited by 41 · see citing works

Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase InhibitorsPreprint

Thomas, R. K., Greulich, H. E., Yuza, Y., LEE, J. C., Tengs, T., Feng, W. W., CHEN, T.-H., Nickerson, E., SIMONS, J., EGHOLM, M., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.056 · Cited by 38 · see citing works

KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies

Maus, M. K. H., Grimminger, P., Mack, P. C., Astrow, S. H., Stephens, C. A., Zeger, G. D., Hsiang, J., Brabender, J., Friedrich, M., Alakus, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.010 · Cited by 34 · see citing works

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer

Soria, J., Fülöp, A., Maciel, C. D., Fischer, J. R., Girotto, G. C., Lago, S., Smit, E. F., Ostoros, G., Eberhardt, W., Lishkovska, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx628 · Cited by 33 · see citing works

Total abdominal colectomy is cost-effective in treating colorectal cancer in patients with genetically diagnosed Lynch Syndrome

Jiang, B., Ofshteyn, A., Idrees, J. J., Giglia, M. D., Gallego, C. J., Stein, S. L., & Steinhagen, E. F. (2019) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2019.03.011 · Cited by 33 · see citing works

VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).

Tabernero, J. M., Chan, E. W., Baselga, J. M., Blay, J., Chau, I., Hyman, D. M., Raje, N. S., Wolf, J., Sirzén, F., Veronese, M. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3518 · Cited by 32 · see citing works

Precision Medicine in Lung Cancer Treatment

Shah, D. R., & Masters, G. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.002 · Cited by 32 · see citing works

Detection of KRAS Mutations and Their Associations with Clinicopathological Features and Survival in Chinese Colorectal Cancer Patients

Li, Z., Chen, Y., Wang, D., Wang, G., He, L., & Suo, J. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000439 · Cited by 30 · see citing works

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

Ciliberto, D., Staropoli, N., Caglioti, F., Chiellino, S., Ierardi, A., Ingargiola, R., Botta, C., Arbitrio, M., Correale, P., Tassone, P., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.003 · Cited by 25 · see citing works

Risk of Malignant Cancers in Inflammatory Bowel Disease

Loo, S. Y., Vutcovici, M., Bitton, A., Lakatos, P. L., Azoulay, L., Suissa, S., & Brassard, P. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz058 · Cited by 25 · see citing works

Comparison of the efficiency of colorectal cancer screening programs based on age and genetic risk for reduction of colorectal cancer mortality

Stanesby, O., & Jenkins, M. A. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2017.60 · Cited by 24 · see citing works

Clinical update on K-Ras targeted therapy in gastrointestinal cancers

Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21 · see citing works

Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer.

Zhao, Y., Ando, K., Oki, E., Ikawa‐Yoshida, A., Ida, S., Kimura, Y., Saeki, H., Kitao, H., Morita, M., & Maehara, Y. (2014) · PubMed · Cited by 17 · see citing works

Two new agents target KRAS G12C

Romero, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0304-3 · Cited by 17 · see citing works

Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations

Yılmaz, A. U., Mohamed, N., Patterson, K. A., Tang, Y., Shilo, K., Villalona-Calero, M. A., Davis, M. E., Zhou, X., Frankel, W. L., Otterson, G. A., et al. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110908645 · Cited by 16 · see citing works

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma

Lilis, I., Ntaliarda, G., Papaleonidopoulos, V., Giotopoulou, G. A., Oπλοποιού, Μ., Marazioti, A., Σπέλλα, Μ., Marwitz, S., Goldmann, T., Bravou, V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593802 · Cited by 15 · see citing works

BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.

Reddy, V. P., Gay, L. M., Elvin, J. A., Vergilio, J., Suh, J. H., Ramkissoon, S. H., Daniel, S., Severson, E. A., Ali, S. M., Schrock, A. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9072 · Cited by 14 · see citing works

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V. D., Rosovsky, R. P. G., Lilenbaum, R., Bastos, B. R., Huang, C. H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.010 · Cited by 14 · see citing works

EGFR targeted therapy for lung cancer: are we almost there?

Metro, G. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.11 · Cited by 9 · see citing works

MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy

Dudnik, E., Peled, N., Wollner, M., Onn, A., Agbareya, A., Nechushtan, H., Kuznetsov, T., Roisman, L. C., Rozenblum, A. B., Geva, S. D., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.455 · Cited by 7 · see citing works

Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability

Matos, P., & Jordan, P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_2 · Cited by 6 · see citing works

SMAD-4 gene expression in human colorectal cancer: Comparison with some clinical and pathological parameters

Wosiak, A., Wodziński, D., Kolasa, M., Sałagacka-Kubiak, A., & Balcerczak, E. I. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.10.013 · Cited by 4 · see citing works

The clinical progress of mRNA vaccines and immunotherapies

Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823 · see citing works

Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants

Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336 · see citing works

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 47 · see citing works

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Malapelle, U., Rossi, G., Pisapia, P., Barberis, M. C. P., Buttitta, F., Castiglione, F., Cecere, F. L., Grimaldi, A. M., Iaccarino, A., Marchetti, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103118 · Cited by 32 · see citing works

Bidirectional Mendelian randomization analysis of the genetic association between primary lung cancer and colorectal cancer

Xiao, Z., Wang, Z., Zhang, T., Liu, Y., & Si, M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04612-7 · Cited by 26 · see citing works

Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids

Banda, M., McKim, K. L., Myers, M. B., Inoue, M., & Parsons, B. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238862 · Cited by 23 · see citing works

Ferroptosis as a Potential Cell Death Mechanism against Cisplatin-Resistant Lung Cancer Cell Line

Golbashirzadeh, M., Heidari, H. R., Talebi, M., & Khosroushahi, A. Y. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.019 · Cited by 12 · see citing works

Identification of candidate biomarkers and therapeutic drugs of colorectal cancer by integrated bioinformatics analysis

Zheng, Z., Xie, J., Xiong, L., Gao, M., Li, Q., Dai, C., Liang, Z., Wang, Y., Xue, J., Wang, Q., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01425-2 · Cited by 11 · see citing works

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis

Shao, J., Olsen, R. J., Kasparian, S., He, C., Bernicker, E., & Li, Z. (2024) · Cells · doi:10.3390/cells13040298 · Cited by 8 · see citing works

Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer

Baek, J. H., Kim, J., Baek, D. W., Chang, E., Kim, H. J., Park, S. Y., Park, J. S., Choi, G., Kang, B. W., & Kim, J. G. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10079 · Cited by 4 · see citing works

Synergizing immunity: lipid nanoparticle-mediated mRNA and gene delivery as a next-gen paradigm in cancer immunotherapy

Roy, A. A., Jain, N., Pokale, R., Madhusoodanan, G., Mukharya, A., Farhana, S. A., Rao, B. S. S., Goda, J. S., & Mutalik, S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126862 · Cited by 3 · see citing works

Cutting-edge Nanotechnological Approaches for Lung Cancer Therapy

Bhattacharya, S., & Agrawal, A. (2022) · Current Drug Research Reviews · doi:10.2174/2589977514666220418085658 · Cited by 3 · see citing works

Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety

Song, J., Wang, Y., Yu, H., Zheng, L., Cai, X., & Chen, Y. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/4227650 · Cited by 2 · see citing works

Declaration of Competing Interest

Cui, W., & Xiang, L. (2024) · Wiley eBooks · doi:10.1002/9783527845583.oth1 · Cited by 3 · see citing works

Case report of metastatic colorectal cancer associated with KRAS A146V and A59G mutations

Kit, O. I., Тимошкина, Н. Н., Gvaldin, D. Y., Soldatkina, N. V., & Gevorkyan, Y. A. (2023) · Sechenov Medical Journal · doi:10.47093/2218-7332.2023.14.2.49-56 · Cited by 1 · see citing works

Comparative Analysis of the Mutational Profile in HBV-Related and Non-HBV-Related Hepatocellular CarcinomaPreprint

Du, B., Wang, H., Yang, J., Wei, Y., & Shao, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-776931/v1

Investigation of biomarkers and associated molecular mechanism shared between colorectal cancer and lung adenocarcinoma

Gao, K., Yu, L., Wang, L., Gao, L., Li, T., & Sun, J. Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03240-5

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance

Morkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 143 · see citing works

Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer

Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55 · see citing works

P-394 RAS/ BRAF molecular profile in metastatic versus non-metastatic colorectal cancer

Douik, H., Sahraoui, G., Charfi, L., Doghri, R., & Mrad, K. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.450

Additional file 1 of Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Araujo, L. H., Souza, B. M., Leite, L. R., Parma, S. A. F., Lopes, N. P., Malta, F. S. V., & Freire, M. C. M. (2021) · Figshare · doi:10.6084/m9.figshare.14121512

Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study

Lee, J., Ahn, J., Park, W. S., Choe, E. K., Kim, E. Y., Shin, R., Heo, S., Jung, S., Kim, K., Chai, Y. J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010111 · Cited by 18 · see citing works